REC610
AssetAlso recombinant zoster vaccine
Recombinant subunit vaccine inducing immune response against varicella-zoster virus glycoprotein E.
- Stage
- Phase 1
- Modality
- Vaccine
- Target
- Not known
- 1
- Indication
- 14
- Trials
- 1
- Developer
Indications
1Herpes zoster
Phase 1, Completed, NCT05769049, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials14
- Evidence for its targets1
- Competitors3
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.